Sage E Hawn1,2, Zoe Neale1,2, Erika J Wolf1,2, Xiang Zhao1,2, Meghan Pierce2,3,4, Dana Fein-Schaffer1, William Milberg3,4, Regina McGlinchey3,4, Mark Logue1,2,5,6, Mark W Miller1,2. 1. National Center for PTSD at VA Boston Healthcare System, Boston, Massachusetts, USA. 2. Department of Psychiatry, Boston University School of Medicine, Boston, Massachusetts, USA. 3. Translational Research Center for TBI and Stress Disorders (TRACTS) and Geriatric Research, Educational and Clinical Center (GRECC), VA Boston Healthcare System, Boston, Massachusetts, USA. 4. Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA. 5. Department of Medicine, Biomedical Genetics, Boston University School of Medicine, Boston, Massachusetts, USA. 6. Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA.
Abstract
BACKGROUND: Posttraumatic stress disorder (PTSD) is associated with inflammation and various forms of chronic disease. The Absent in Melanoma 2 (AIM2) gene has been implicated in mechanisms of inflammation and anxiety, and methylation at a particular locus in this gene (cg10636246) has previously been shown to influence the association between PTSD and elevated C-reactive protein levels in blood. METHOD: We tested if this association might extend to other indicators of inflammation and to plasma-based measures of neuropathology in a cohort of post-9/11 US military veterans. Using a Bayesian approach, mediation models were tested cross-sectionally (n = 478) and longitudinally (n = 298). Peripheral markers of inflammation and neuropathology were measured with ultra-sensitive Single Molecule Array (Simoa®) technology. RESULTS: Analyses revealed indirect effects of PTSD symptom severity on peripheral indices of both inflammation (interleukin [IL]6, IL-10, tumor necrosis factor-α; indirect standardized [std.] ß range = 0.018-0.023, all p-values adjusted for multiple testing [padj ] < 0.05) and neuropathology (neurofilament light [NFL]; indirect std. ß = -0.018, padj = 0.02) via AIM2 methylation. This indirect effect was also evident when predicting IL-10 at a follow-up assessment (indirect std. ß = -0.018, padj = 0.04) controlling for baseline IL-10. CONCLUSIONS: Given that AIM2 methylation mediated the association between PTSD symptoms and multiple inflammatory and neuropathology markers, our results suggest that AIM2 methylation may offer clinical utility for indexing risk for adverse health outcomes associated with these peripheral indices of inflammation and neuropathology. Results also suggest a possible shared etiology underlying the frequent co-occurrence of inflammation and neuropathology. Published 2022. This article is a U.S. Government work and is in the public domain in the USA.
BACKGROUND: Posttraumatic stress disorder (PTSD) is associated with inflammation and various forms of chronic disease. The Absent in Melanoma 2 (AIM2) gene has been implicated in mechanisms of inflammation and anxiety, and methylation at a particular locus in this gene (cg10636246) has previously been shown to influence the association between PTSD and elevated C-reactive protein levels in blood. METHOD: We tested if this association might extend to other indicators of inflammation and to plasma-based measures of neuropathology in a cohort of post-9/11 US military veterans. Using a Bayesian approach, mediation models were tested cross-sectionally (n = 478) and longitudinally (n = 298). Peripheral markers of inflammation and neuropathology were measured with ultra-sensitive Single Molecule Array (Simoa®) technology. RESULTS: Analyses revealed indirect effects of PTSD symptom severity on peripheral indices of both inflammation (interleukin [IL]6, IL-10, tumor necrosis factor-α; indirect standardized [std.] ß range = 0.018-0.023, all p-values adjusted for multiple testing [padj ] < 0.05) and neuropathology (neurofilament light [NFL]; indirect std. ß = -0.018, padj = 0.02) via AIM2 methylation. This indirect effect was also evident when predicting IL-10 at a follow-up assessment (indirect std. ß = -0.018, padj = 0.04) controlling for baseline IL-10. CONCLUSIONS: Given that AIM2 methylation mediated the association between PTSD symptoms and multiple inflammatory and neuropathology markers, our results suggest that AIM2 methylation may offer clinical utility for indexing risk for adverse health outcomes associated with these peripheral indices of inflammation and neuropathology. Results also suggest a possible shared etiology underlying the frequent co-occurrence of inflammation and neuropathology. Published 2022. This article is a U.S. Government work and is in the public domain in the USA.
Entities:
Keywords:
DNA methylation; PTSD; inflammation; neuropathology; single molecule array
Authors: Catherine R Lammert; Elizabeth L Frost; Calli E Bellinger; Ashley C Bolte; Celia A McKee; Mariah E Hurt; Matt J Paysour; Hannah E Ennerfelt; John R Lukens Journal: Nature Date: 2020-04-08 Impact factor: 49.962
Authors: Heidi Högel; Eero Rissanen; Christian Barro; Markus Matilainen; Marjo Nylund; Jens Kuhle; Laura Airas Journal: Mult Scler Date: 2018-12-20 Impact factor: 6.312
Authors: David M Rissin; David R Fournier; Tomasz Piech; Cheuk W Kan; Todd G Campbell; Linan Song; Lei Chang; Andrew J Rivnak; Purvish P Patel; Gail K Provuncher; Evan P Ferrell; Stuart C Howes; Brian A Pink; Kaitlin A Minnehan; David H Wilson; David C Duffy Journal: Anal Chem Date: 2011-02-23 Impact factor: 6.986
Authors: Frank W Weathers; Michelle J Bovin; Daniel J Lee; Denise M Sloan; Paula P Schnurr; Danny G Kaloupek; Terence M Keane; Brian P Marx Journal: Psychol Assess Date: 2017-05-11
Authors: M W Miller; H Maniates; E J Wolf; M W Logue; S A Schichman; A Stone; W Milberg; R McGlinchey Journal: Brain Behav Immun Date: 2017-09-01 Impact factor: 7.217
Authors: Vijay A K Rathinam; Zhaozhao Jiang; Stephen N Waggoner; Shruti Sharma; Leah E Cole; Lisa Waggoner; Sivapriya Kailasan Vanaja; Brian G Monks; Sandhya Ganesan; Eicke Latz; Veit Hornung; Stefanie N Vogel; Eva Szomolanyi-Tsuda; Katherine A Fitzgerald Journal: Nat Immunol Date: 2010-03-28 Impact factor: 25.606
Authors: S Balducci; S Zanuso; A Nicolucci; F Fernando; S Cavallo; P Cardelli; S Fallucca; E Alessi; C Letizia; A Jimenez; F Fallucca; G Pugliese Journal: Nutr Metab Cardiovasc Dis Date: 2009-08-19 Impact factor: 4.222
Authors: Regina E McGlinchey; William P Milberg; Jennifer R Fonda; Catherine Brawn Fortier Journal: Int J Methods Psychiatr Res Date: 2017-02-17 Impact factor: 4.035